Skip to main content
Clinical Trials/NCT04019808
NCT04019808
Completed
Not Applicable

Interventional Study at the Primary and Secondary Levels of Prevention for Knowledge Regarding GC Risk Factors in EU and CELAC Populations

Fundación para la Investigación del Hospital Clínico de Valencia8 sites in 7 countries800 target enrollmentJuly 30, 2019
ConditionsGastric Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Gastric Cancer
Sponsor
Fundación para la Investigación del Hospital Clínico de Valencia
Enrollment
800
Locations
8
Primary Endpoint
knowledge GC risk factors and symptoms
Status
Completed
Last Updated
last year

Overview

Brief Summary

This study is divided into two parts:

Part 1: An interventional study, with a pre-post study design to determinate the grade of knowledge of established GC risk factors.

Part 2: An observational study to know impact on prevalence and infection eradication of H. pylori

Detailed Description

Part 1: to determinate the grade of knowledge of established GC risk factors and identification of attitudes about, GC screening programs at baseline, prior to the intervention though an educational program. Part 2: to generate an H. pylori registry, to know its impact on prevalence and infection eradication rate at 6th, 12th, 24th and at Month 36th.

Registry
clinicaltrials.gov
Start Date
July 30, 2019
End Date
December 31, 2023
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Fundación para la Investigación del Hospital Clínico de Valencia
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

knowledge GC risk factors and symptoms

Time Frame: 3 years

Compare the results obtained through a knowledge of CG risk factors by study-specific questionnaire before and after an educational intervention

H. pylori prevalence and drug resistance

Time Frame: 3 years

Generate an H. pylori registry, to know its impact on prevalence and infection eradication rate at months 6th, 12th, 24th and 36th.

Study Sites (8)

Loading locations...

Similar Trials